

Entrectinib STARTRK-1; STARTRK-2; ALKA-372-001

### PRELIMINARY SCORE

**CURATIVE**



**NON-CURATIVE**



### ADJUSTMENTS

**Quality of life**



**Serious and disabling adverse effects**



**Other adjustments**



Entrectinib STARTRK-1; STARTRK-2; ALKA-372-001

### FINAL SCORE

**CURATIVE**



Overall Survival / Disease-Free Survival / Pathological Complete Response

**NON-CURATIVE**



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

**INFORMATION**

Tumour type: Refractory NTRK fusion-positive cancers  
 Therapeutic Indication: Treatment of adult and paediatric patients older than 1 month with solid tumours that have NTRK gene fusion, who have disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and who have not received a prior NTRK inhibitor, and who have no satisfactory treatment options.  
 Experimental Arm: Entrectinib  
 Control Arm: Single arm trials (Phase I/II)



